<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285478</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 13.03</org_study_id>
    <nct_id>NCT02285478</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Once Daily Darunavir/Ritonavir in HIV-infected Children</brief_title>
  <acronym>DAPHNE</acronym>
  <official_title>Once Daily Darunavir/Ritonavir in HIV-infected Children 6-12 Years Old: a Pharmacokinetic Validation of Model Based Dosing Recommendations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Darunavir/ritonavir is one of the preferred antiretroviral agents as part of combination&#xD;
      antiretroviral therapy for treatment of HIV-infected adults according to international&#xD;
      guidelines. For children 3-12 years old, FDA has approved once daily dosing of&#xD;
      darunavir/ritonavir. Dosing recommendations for children 6-12 years old have been approved&#xD;
      based on a modelling and simulation procedure by the company.&#xD;
&#xD;
      This pharmacokinetic study is designed to validate the proposed dosing recommendation for&#xD;
      once daily darunavir/ritonavir in HIV-infected children aged 6-12 years old.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EMA and FDA recommended weight band dosing for once daily DRV/r dosing in children 3 -12&#xD;
      years of age has been derived from pharmacokinetic modelling. Results from population&#xD;
      pharmacokinetic modelling and simulation in these children predict similar DRV plasma&#xD;
      exposures compared to treatment-na√Øve adults, but has not been formally studied in the target&#xD;
      population. Although no clinical trial was conducted to collect exposure-safety data, the&#xD;
      predicted exposures from the once daily dosing is supported by exposures observed in a&#xD;
      paediatric clinical trial where twice-daily dosing was administered. To validate the weight&#xD;
      band based dosing recommendations, we want to evaluate the pharmacokinetics of DRV/r&#xD;
      administered once daily, using DRV tablets, in HIV-infected children.&#xD;
&#xD;
      Darunavir/ritonavir is one of the preferred antiretroviral agents as part of combination&#xD;
      antiretroviral therapy for treatment of HIV-infected adults according to international&#xD;
      guidelines. For children 3-12 years old, FDA has approved once daily dosing of&#xD;
      darunavir/ritonavir. Dosing recommendations for children 6-12 years old have been approved&#xD;
      based on a modelling and simulation procedure by the company.&#xD;
&#xD;
      This pharmacokinetic study is designed to validate the proposed dosing recommendation for&#xD;
      once daily darunavir/ritonavir in HIV-infected children aged 6-12 years old.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The exposure of darunavir, compared to the target exposure (AUC0-24) in adults</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Children</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected children (6-12 years) using once daily darunavir/ritonavir.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Parents/carers are able and willing to sign the informed consent form prior to&#xD;
             screening evaluations&#xD;
&#xD;
          2. Subject is HIV infected&#xD;
&#xD;
          3. Subject is at least 6 and less than 12 years at day of screening&#xD;
&#xD;
          4. Subject has a body weight of at least 15kg&#xD;
&#xD;
          5. Subject is able to swallow tablets&#xD;
&#xD;
          6. Subject has an undetectable viral load (&lt;50 copies/mL) for the last 6 months prior to&#xD;
             screening (at least 2 measurements)&#xD;
&#xD;
          7. ART regimen consists of darunavir/ritonavir and 2 NRTIs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to understand the nature and extent of the trial and the procedures required&#xD;
&#xD;
          2. Documented history of sensitivity/idiosyncrasy to darunavir or ritonavir medicinal&#xD;
             products or its excipients&#xD;
&#xD;
          3. Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion&#xD;
&#xD;
          4. Abnormal renal or liver function (grade 3 or above)&#xD;
&#xD;
          5. Participation in a drug trial within 60 days prior to the first dose&#xD;
&#xD;
          6. Hemoglobin &lt; 10 g/dL (6.0 mmol/L)&#xD;
&#xD;
          7. Children who have previously failed virologically on a PI containing regimen (where&#xD;
             virological failure is defined as two successive HIV-1 RNA results &gt;1,000 c/mL more&#xD;
             than 24 weeks after starting cART, i.e. changes for toxicity or convenience are not&#xD;
             counted as failure)&#xD;
&#xD;
          8. Acute illness&#xD;
&#xD;
          9. Receiving concomitant therapy except for prophylaxis for opportunistic infections;&#xD;
             some treatments may be allowed, but must first be discussed with the principal&#xD;
             investigator or project manager.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Burger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Bastiaans DET, Geelen SPM, Visser EG, van der Flier M, Vermont CL, Colbers APH, Roukens M, Burger DM, van Rossum AMC; Dutch Paediatric HIV Study Group. Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children. Pediatr Infect Dis J. 2018 Oct;37(10):1008-1010. doi: 10.1097/INF.0000000000001964.</citation>
    <PMID>29474261</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2014</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

